Binge Eating Disorder Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2000

Binge Eating disorder Pipeline Drugs Market Report Overview

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Binge Eating Disorder – Drugs In Development, 2022, provides an overview of the Binge Eating Disorder (Central Nervous System) pipeline landscape.

Binge eating disorder is a serious condition characterized by uncontrollable eating and resulting weight gain. The causes of binge-eating disorder are unknown. But family history, biological factors, long-term dieting and psychological issues increase risk. Signs and symptoms include eating unusually large amounts of food, frequently eating alone, feeling that eating behavior is out of control and experiencing depression and anxiety. Treatment includes psychotherapy, medications and behavioral weight-loss programs.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Binge Eating Disorder – Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Binge Eating Disorder (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Binge Eating Disorder (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Binge Eating Disorder and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 4, 7 and 1 respectively.

Binge Eating Disorder (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

* Global Markets Direct, is a research brand owned and operated by GlobalData.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Binge Eating Disorder (Central Nervous System).

– The pipeline guide reviews pipeline therapeutics for Binge Eating Disorder (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Binge Eating Disorder (Central Nervous System) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Binge Eating Disorder (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Binge Eating Disorder (Central Nervous System)

Reasons to Buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

– Find and recognize significant and varied types of therapeutics under development for Binge Eating Disorder (Central Nervous System).

– Classify potential new clients or partners in the target demographic.

– Develop tactical initiatives by understanding the focus areas of leading companies.

– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

– Formulate corrective measures for pipeline projects by understanding Binge Eating Disorder (Central Nervous System) pipeline depth and focus of Indication therapeutics.

– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Amygdala Neurosciences Inc
AWAKN Life Sciences Corp
Bioprojet SCR
Bright Minds Biosciences Inc
Chronos Therapeutics Ltd
Clearmind Medicine Inc
F. Hoffmann-La Roche Ltd
Omeros Corp
Otsuka Pharmaceutical Co Ltd
OXonium Therapeutics
Trigemina Inc
Tryp Therapeutics Inc
Yichang Renfu Pharmaceutical Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Binge Eating Disorder – Overview

Binge Eating Disorder – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Binge Eating Disorder – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Binge Eating Disorder – Companies Involved in Therapeutics Development

Amygdala Neurosciences Inc

AWAKN Life Sciences Corp

Bioprojet SCR

Bright Minds Biosciences Inc

Chronos Therapeutics Ltd

Clearmind Medicine Inc

F. Hoffmann-La Roche Ltd

Omeros Corp

Otsuka Pharmaceutical Co Ltd

OXonium Therapeutics

Trigemina Inc

Tryp Therapeutics Inc

Yichang Renfu Pharmaceutical Co Ltd

Binge Eating Disorder – Drug Profiles

ANS-6637 – Drug Profile

Product Description

Mechanism Of Action

History of Events

BMB-101 – Drug Profile

Product Description

Mechanism Of Action

History of Events

BP-1.4979 – Drug Profile

Product Description

Mechanism Of Action

History of Events

centanafadine SR – Drug Profile

Product Description

Mechanism Of Action

History of Events

CMND-100 – Drug Profile

Product Description

Mechanism Of Action

CT-010018 – Drug Profile

Product Description

Mechanism Of Action

History of Events

CTDP-002 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Drugs to Antagonize Ox1 Receptor for Binge Eating Disorder – Drug Profile

Product Description

Mechanism Of Action

ketamine – Drug Profile

Product Description

Mechanism Of Action

History of Events

lisdexamphetamine dimesylate – Drug Profile

Product Description

Mechanism Of Action

OMS-527 – Drug Profile

Product Description

Mechanism Of Action

History of Events

oxytocin – Drug Profile

Product Description

Mechanism Of Action

History of Events

psilocybin – Drug Profile

Product Description

Mechanism Of Action

History of Events

RO-5256390 – Drug Profile

Product Description

Mechanism Of Action

History of Events

TRP-8803 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Binge Eating Disorder – Dormant Projects

Binge Eating Disorder – Discontinued Products

Binge Eating Disorder – Product Development Milestones

Featured News & Press Releases

Jun 29, 2022: Tryp Therapeutics strengthens IP portfolio with provisional patent application for binge eating disorder treatment

Jun 09, 2022: Tryp Therapeutics announces results of first patient dosed in its phase II clinical trial for the treatment of binge eating disorder

May 26, 2022: Awakn Life Sciences files Patent Cooperation Treaty (PCT) Application for the treatment of behavioral addictions

May 10, 2022: SciSparc and Clearmind Medicine collaboration yields new patent application for psychedelic combination treatment for binge behaviors

Apr 28, 2022: Tryp Therapeutics doses first patient in phase II psilocybin-assisted therapy clinical trial

Mar 23, 2022: Tryp Therapeutics initiates enrollment for binge eating disorder study in partnership with University of Florida

Jan 05, 2022: Awakn Life Sciences expands world’s first ketamine study beyond gambling disorder to include additional behavioral addictions

Dec 23, 2021: Tryp Therapeutics announces advancement of phase 2a clinical trial in binge eating disorder

Dec 03, 2021: Tryp Therapeutics to present at the H.C. Wainwright Psychedelics Conference on December 6, 2021

Nov 18, 2021: Tryp Therapeutics provides update on clinical hold for phase 2a study for eating disorders

Sep 22, 2021: Bright Minds Biosciences provides scientific update

Mar 03, 2021: Bright Minds Biosciences (“BMB”) proprietary 5-HT2C agonists show significant reduction in binge eating

May 02, 2018: Chronos Therapeutics announces positive pre-clinical proof of concept studies for its Orexin-1 antagonist project initially targeting binge eating disorder

Oct 06, 2016: Study Finds New Approach to Block Binge Eating

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Binge Eating Disorder, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Binge Eating Disorder – Pipeline by Amygdala Neurosciences Inc, 2022

Binge Eating Disorder – Pipeline by AWAKN Life Sciences Corp, 2022

Binge Eating Disorder – Pipeline by Bioprojet SCR, 2022

Binge Eating Disorder – Pipeline by Bright Minds Biosciences Inc, 2022

Binge Eating Disorder – Pipeline by Chronos Therapeutics Ltd, 2022

Binge Eating Disorder – Pipeline by Clearmind Medicine Inc, 2022

Binge Eating Disorder – Pipeline by F. Hoffmann-La Roche Ltd, 2022

Binge Eating Disorder – Pipeline by Omeros Corp, 2022

Binge Eating Disorder – Pipeline by Otsuka Pharmaceutical Co Ltd, 2022

Binge Eating Disorder – Pipeline by OXonium Therapeutics, 2022

Binge Eating Disorder – Pipeline by Trigemina Inc, 2022

Binge Eating Disorder – Pipeline by Tryp Therapeutics Inc, 2022

Binge Eating Disorder – Pipeline by Yichang Renfu Pharmaceutical Co Ltd, 2022

Binge Eating Disorder – Dormant Projects, 2022

Binge Eating Disorder – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Binge Eating Disorder, 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently asked questions

Binge Eating Disorder Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Binge Eating Disorder Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Binge Eating Disorder Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.